Skip to main content

CLASS ACTION UPDATE for SRAC, OCGN and CRMD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / August 1, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

SRAC Shareholders Click Here: https://www.zlk.com/pslra-1/stable-road-acquisition-corp-information-request-form-2?prid=18132&wire=1 
OCGN Shareholders Click Here: https://www.zlk.com/pslra-1/ocugen-inc-information-request-form?prid=18132&wire=1 
CRMD Shareholders Click Here: https://www.zlk.com/pslra-1/cormedix-inc-loss-submission-form?prid=18132&wire=1 
 

* ADDITIONAL INFORMATION BELOW * 

Stable Road Acquisition Corp. (NASDAQ:SRAC)

SRAC Lawsuit on behalf of: investors who purchased October 7, 2020 - July 13, 2021
Lead Plaintiff Deadline : September 13, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/stable-road-acquisition-corp-information-request-form-2?prid=18132&wire=1

According to the filed complaint, during the class period, Stable Road Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose that: (a) Stable Road's acquistion target, Momentus's 2019 test of its key technology, a water plasma thruster, had failed to meet Momentus's own public and internal pre-launch criteria for success, and was conducted on a prototype that was not designed to generate commercially significant amounts of thrust; (b) the U.S. government had conveyed that it considered Momentus's Chief Executive Officer a national security threat, jeopardizing his continued leadership of Momentus and Momentus's launch schedule and business prospects; (c) consequently, the revenue projections and business and operational plans provided to investors regarding Momentus and the commercial viability and timeline of its products were materially false and misleading and lacked a reasonable basis in fact; and (d) Stable Road had failed to conduct appropriate due diligence of Momentus and its business operations and defendants had materially misrepresented the due diligence activities being conducted by Stable Road executives and its sponsor in connection with the merger.

Ocugen, Inc. (NASDAQ:OCGN)

OCGN Lawsuit on behalf of: investors who purchased February 2, 2021 - June 10, 2021
Lead Plaintiff Deadline : August 17, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ocugen-inc-information-request-form?prid=18132&wire=1

According to the filed complaint, during the class period, Ocugen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

CorMedix Inc. (NASDAQ:CRMD)

CRMD Lawsuit on behalf of: investors who purchased July 8, 2020 - May 13, 2021
Lead Plaintiff Deadline : September 20, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cormedix-inc-loss-submission-form?prid=18132&wire=1

According to the filed complaint, during the class period, CorMedix Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: 
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com 
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/657916/CLASS-ACTION-UPDATE-for-SRAC-OCGN-and-CRMD-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.